<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359344</url>
  </required_header>
  <id_info>
    <org_study_id>1014802/101</org_study_id>
    <secondary_id>2014-004980-19</secondary_id>
    <nct_id>NCT02359344</nct_id>
  </id_info>
  <brief_title>PK &amp; Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo controlled, two period crossover study to investigate the
      pharmacokinetics, tolerability and cognitive effects of 8 days dosing of CNV1014802 in
      healthy young versus elderly male and female subjects. Treatment periods will be separated by
      13 days. The primary outcome measures are pharmacokinetics (PK) and tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been
      acquired by Biogen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2015</start_date>
  <completion_date type="Actual">April 20, 2015</completion_date>
  <primary_completion_date type="Actual">April 20, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration curve</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vital signs compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 12-lead ECG parameters compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in safety lab parameters compared to baseline</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>CNV1014802</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tid 7 days plus a single dose on day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNV1014802</intervention_name>
    <arm_group_label>CNV1014802</arm_group_label>
    <other_name>BIIB074</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy male and female over 18 years using acceptable methods of contraception

        Key Exclusion Criteria:

          -  Positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody

          -  History or evidence of alcohol or drug abuse

          -  Pregnant or lactating females

          -  Participation in a clinical trial within 3 months or the current study or exposure to
             more than four new chemical entities within 12 months.

          -  Use of prohibited concomitant medication

          -  History or presence of any clinically significant abnormality in vital signs / ECG /
             laboratory tests, or have any medical or psychiatric condition, which, in the opinion
             of the Investigator may interfere with the study procedures or compromise subject
             safety.

          -  Relevant history of a suicide attempt or suicidal behavior

        Note: Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Trigeminal Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

